Relinia, Inc.

Other

Axys Pharmaceuticals, Inc.

Lutz B Giebel

Leonard G Presta

David C Foster

Harvey F Lodish

David J Matthews

Michael Peter Ross

Kevin R Shoemaker

Warak Lee Chaovapong

Xin Liu

Michael J Ross

Cyrus Karkaria

Hong Wu

Helmut H Schneider

This invention provides for a fusion protein between a single chain TNFR2 Selective Agonist protein (scTNFR2 Selective Agonist) and a dimerization domain, such as an IgGFc protein. The single chain TNFR2 Selective Agonist moiety provides a therapeutic activity by selectively activating the TNFR2 form of the TNF-α receptor, thus selectively stimulating Tregs and/or increasing myelin deposition.

Single-chain TNF Receptor 2 agonist fusion proteins

This invention provides for a fusion protein between a single chain TNFR2 Selective Agonist protein (scTNFR2 Selective Agonist) and a dimerization domain, such as an IgGFc protein. The single chain TNFR2 Selective Agonist moiety provides a therapeutic activity by selectively activating the TNFR2 form of the TNF-&#x3b1; receptor, thus selectively stimulating Tregs and/or increasing myelin deposition.

Single-chain TNF receptor 2 agonist fusion proteins

Transgenic nonhuman mammals, such as transgenic mice, which lack erythropoietin expression, in which the erythropoietin receptor is deleted, which carry a heterologous erythropoietin receptor (e.g., a chimeric receptor); constructs useful for producing such transgenic nonhuman mammals, embryonic stem cells containing the constructs, a method of producing the transgenic nonhuman mammals and a method of identifying erythropoietin mimics or mimetics.

TRANSGENIC MAMMALS LACKING EXPRESSION OF ERYTHROPOIETIN OR OF ERYTHROPOIETIN RECEPTOR, TRANSGENIC MAMMALS EXPRESSING CHIMERIC ERYTHROPOIETIN RECEPTORS, CONSTRUCTS FOR PRODUCING THE TRANSGENIC MAMMALS AND USES THEREFOR

Antibodies and Bivalent molecules which activate erythropoietins and induce the proliferation or differentiation of erythroid progenitor cells are provided. Also provided are methods of using such bivalent molecules for drug discovery, diagnosis and treatment of disorders related to the activation of an erythropoietin receptor.

Bivalent molecules that form an activating complex with an

Growing community of inventors

San Mateo, CA, United States of America

Lutz B Giebel